Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Transplant Cell Ther. 2021 Feb 4;27(5):389.e1–389.e10. doi: 10.1016/j.jtct.2021.02.002

Figure 5. Ruxolitinib blocks IFNγ induced CX3CL1 and CCL2 on MSCs.

Figure 5.

MSCs (10000 cells/ well) were seeded in 96 well plate and treated with +/− IFNγ (20 ng/mL) and different concentrations of Ruxolitinib for up to 3 days. The supernatants were collected on day 3 and quantitative levels of CCL2, CX3CLl and VEGF were assayed through Luminex xMAP (multi-analyte profiling) technology. Dose dependent effect of Ruxolitinib on the concentrations of (A) CCL2, (B) CX3CLl and (C) VEGF is shown on two independent MSC donors (Left: MSC Donor#1, Right: MSC Donor#2). Y axis represents the concentration in Picogram/milliliter. Average concentration with standard deviation is plotted. Assays were done in duplicates and were run in the Luminex system independently. Two-Way ANOVA multiple comparison test was performed between 0 nM and other Ruxolitinib concentrations. **, ***, **** represents P ≤ 0.01, P ≤ 0.001 and P ≤ 0.0001 respectively.